Doctor: I picked up attributes in the hospital

Optimal solution
Three in the afternoon.

Stem cell culture room.

"Doctor Zhao, you said there is another patient who needs to be cultured with epithelial stem cells?"

Qu Xiaofeng asked Zhao Heng. He didn't expect that in just two days, there would be another patient who needed stem cell therapy.

"Yes, it's a patient just admitted yesterday, with verrucous epidermis dysplasia, who has undergone seven surgeries before coming here."

Zhao Heng said.

"Verturous epidermis dysplasia? After seven operations, there is no cancer. This patient's constitution is really special."

As a pathologist, Qu Xiaofeng is very familiar with various diseases, especially those that can cause cancer.

"That's true. Originally, I thought about whether we could use gene-targeted therapy to cure warts, but Professor Li Hongwei said this morning that at present, the use of gene-targeted therapy to cure warts has not yet been achieved in China or even in the world. The technical level of genetic diseases such as epidermal dysplasia.

Zhao Heng said with a little regret.

In modern society, every technology cannot be conquered by one person. It requires a very good team, sufficient funds, and a lot of time and energy to overcome it.

As for the EPS cells developed by Professor Li Hongwei, it took him and his mentor nearly two generations to finally develop them, and it will take at least a few years before the research can be put into clinical use.

Scientific research, especially the overcoming of a technology, is so difficult.

Perhaps a breakthrough in theory can be made by a scientist's flash of inspiration, but a breakthrough in practical application technology can only be solved bit by bit by spending a lot of manpower and material resources.

Compared with finance, real estate and the Internet, technology research and development, especially in the field of life sciences, is to some extent cost-effective and thankless.

This is why it is difficult for almost new drugs and new technologies to appear in China.

"That's true. Stem cell culture and treatment are already difficult enough. This gene-targeted therapy technology is more than twice as difficult as stem cell therapy. I don't think this kind of technology will be seen in a short time. The hope of clinical application, especially in China, the application of this technology is even more distant."

As a pathologist, Qu Xiaofeng has a good understanding of various cancers, and the targets of gene-targeted therapy are various genetic diseases and cancers.

After all, the occurrence of cancer is mostly related to the activation of proto-oncogenes in the human genome.

"Do not mention the domestic scientific research environment."

Zhao Heng shook his head slightly and said.

Anyone who knows the environment of scientific research in China knows it, so there is no need to say more.

"Dr. Zhao, as long as we do a good job in the field of stem cell therapy, I think it will be very good. As for gene-targeted therapy, it is too far away from us."

Qu Xiaofeng said with a sigh.

To be honest, being able to conduct stem cell therapy at Dongfang Hospital, in Qu Xiaofeng's opinion, is already a high-spirited.

For many diseases, especially rare diseases and intractable diseases, domestic research is actually very little. Once someone has these rare diseases, they can only buy special drugs developed abroad at high prices.

This high price is really unimaginably high.

For now, just this year, the beautiful country FDA announced that the Australian pharmaceutical company CSL Behring's one-time gene therapy Hemgenix for the treatment of hemophilia B has been approved, priced at $350 million, breaking the record for the most expensive treatment in the world Record.

In less than half a year, the "world's most expensive drug" has changed hands three times.In August of this year, Zynteglo, a gene therapy product for the treatment of patients with β-thalassemia, launched by the beautiful country, was priced at US$8 million, breaking Novartis' Zolgensma to become the most expensive drug; then in September, it launched the second The gene therapy drug Skysona, which is used to slow down the progression of neurological dysfunction in boys with early active cerebral adrenoleukodystrophy (CALD) aged 280-9, is priced at $4 million, breaking another price record.

350 million U.S. dollars, according to the current exchange rate, that is nearly 2400 million soft sister coins. It is really unimaginable for ordinary people to spend so much money on medical treatment. In other words, if ordinary people get this disease, then I can only wait to die.

"That's right, to develop targeted genetic medicines for the treatment of genetic diseases such as verrucous epidermis, it would cost at least hundreds of millions of dollars. In China, this kind of scientific research investment is completely unimaginable to us."

Zhao Heng said with a sigh.

Although at present, with the blessing of Golden Finger, his medical technology level has reached the peak of Dongfang Hospital in all aspects, it can be said that there is basically no doctor who can match him.

But in the field of scientific research, he is just a rookie. In the past ten years, he has not heard of any doctor in Dongfang Hospital who has researched anything amazing.

The only one who has made some achievements in the field of scientific research is Liu Shangming, the director of the oncology department, who is also the current dean. He has developed several cancer treatment drugs, which are said to be treatments, but in fact they can only slow down cancer. function of cell growth.

The combined value of these drugs is only over [-] million. Compared with the world's top pharmaceutical and biological companies, which spend more than one billion US dollars in research and development, this over [-] million soft sister currency is simply incomparable.

"Dr. Zhao, in fact, the method of cultivating epithelial stem cells can be used to treat verrucous epidermal dysplasia. This is already a pioneering work in the treatment of this disease. In addition to surgery, as long as the treatment is done properly, the chance of recurrence in the future is Extremely low."

Qu Xiaofeng said slowly, he is still a more pragmatic person, in his opinion, Zhao Heng's thinking is broad enough, the current doctors, due to the shortage of medical resources, have to see too many patients every day .

Because there are too many patients on hand, the doctors are exhausted. This is more obvious in higher-level hospitals.

Therefore, in this general environment, Zhao Heng can still think of innovative treatment methods, which is already very commendable.

This is also the reason why the directors of several departments value Zhao Heng so much. It is because they have seen such a rare quality in him, which is really lacking in the current young doctors.

"That's the only way to go now."

Zhao Heng nodded. Technological breakthroughs cannot be achieved in a short while, so we can only find ways to come up with an optimal solution under the existing conditions.

This is also no way.

(End of this chapter)